Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Journal of Cancer

• Publication date

  2015-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejca.2015.05.017PMID 26049686
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab.

  2014cited by this paper
• PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.

  2014cited by this paper
• 549PIMPACT OF TUMOUR RAS/BRAF STATUS ON EFFICACY OF FIRST-LINE PANITUMUMAB + FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC).

  2014cited by this paper
• Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

  2014cited by this paper
• FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC).

  2014cited by this paper
• Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.

  2014cited by this paper
• BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer

  2014cited by this paper
• Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2014cited by this paper
• Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

  2014cited by this paper
• Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.

  2014cited by this paper
• Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

  2013cited by this paper
• Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

  2013cited by this paper
• Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective

  2012cited by this paper
• Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.

  2012cited by this paper
• Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.

  2012cited by this paper
• KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

  2011cited by this paper
• Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer

  2011cited by this paper
• Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

  2010cited by this paper
• Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

  2010cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

  2008cited by this paper
• KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

  2008cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• Cetuximab for the treatment of colorectal cancer.

  2007cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper

• Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer.

  2025cites this paper
• Multimodal Preoperative Management of Rectal Cancer: A Review of the Existing Guidelines

  2025cites this paper
• A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial.

  2025cites this paper
• Beneath the surface of Colorectal Cancer: unmasking the evolving nature of (Neo)RAS.

  2025cites this paper
• de novo metastases in patients with primary colorectal cancer: a Surveillance, Epidemiology, and End Results analysis

  2025cites this paper
• Regional and Gender-Based Distribution of KRAS Mutations in Metastatic Colorectal Cancer Patients in Turkey: An Observational Study

  2025influential citation
• Oncogenic RAS induces a distinctive form of non-canonical autophagy mediated by the P38-ULK1-PI4KB axis

  2025cites this paper
• A Narrative Review of RAS Mutations in Early-Stage Colorectal Cancer: Mechanisms and Clinical Implications

  2025cites this paper
• The mutational spectrum of NRAS gene discovers a novel frameshift mutation (E49R) in Saudi colorectal cancer patients

  2025cites this paper
• Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study

  2024cites this paper
• Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study

  2024cites this paper
• Exploring somatic mutations in BRAF, KRAS, and NRAS as therapeutic targets in Saudi colorectal cancer patients through massive parallel sequencing and variant classification

  2024cites this paper
• RAS, BRAF, and MMR system mutations in metastatic colorectal cancers: an observational study

  2024cites this paper
• Cancer treatment monitoring using cell-free DNA fragmentomes

  2024cites this paper
• The discovery and simulation analysis of a novel mutation c.40 G < T (V14F) in the NRAS gene in patients with colorectal cancer in Saudi Arabia

  2024cites this paper
• The RAS/BRAF genes status in patients with colorectal cancer (review)

  2024cites this paper
• The challenge of molecular selection in liver-limited metastatic colorectal cancer for surgical resection: a systematic review and meta-analysis in the context of current and future approaches

  2024cites this paper
• Emerging role of liquid biopsy in rat sarcoma virus mutated metastatic colorectal cancer: A case report

  2024cites this paper
• Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer

  2023influential citation
• Identifying Genetic Mutation Status in Patients with Colorectal Cancer Liver Metastases Using Radiomics-Based Machine-Learning Models

  2023cites this paper
• Anti-epidermal growth factor receptor treatment for patients with NeoRAS wild-type metastatic colorectal cancer: a case report of two cases

  2023cites this paper
• Intestinal transit-amplifying cells require METTL3 for growth factor signaling and cell survival

  2023cites this paper
• METASTATİK KOLOREKTAL KANSERLİ HASTALARIN EGFR YA DA VEGF İNHİBİTÖRÜ KULLANIM DURUMLARINA GÖRE KLİNİK ÖZELLİKLERİNİN İNCELENMESİ

  2023cites this paper
• ctDNA-guided adjuvant treatment after radical-intent treatment of metastatic spread from colorectal cancer—the first interim results from the OPTIMISE study

  2023cites this paper
• Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

  2023cites this paper
• Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania

  2023cites this paper
• Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial

  2023cites this paper
• Intestinal transit amplifying cells require METTL3 for growth factor signaling, KRAS expression, and cell survival

  2023cites this paper
• KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas

  2023cites this paper
• The Impact of Molecular Biology in the Seeding, Treatment Choices and Follow-Up of Colorectal Cancer Liver Metastases—A Narrative Review

  2023cites this paper
• Asparaginyl endopeptidase contributes to cetuximab resistance via MEK/ERK signaling in RAS wide-type metastatic colorectal cancer

  2023cites this paper
• Somatic mutations in colorectal cancer: regional experience

  2022cites this paper
• Molecularly targeted therapy in metastatic CRC

  2022cites this paper
• Reexposición de la terapia con Anti-EGFR en pacientes con cáncer colorrectal metastásico RAS/BRAF tipo salvaje

  2022cites this paper
• Estudio de RAS/BRAF en biopsia líquida en cáncer de colon metastásico

  2022cites this paper
• Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study

  2022cites this paper
• Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue

  2022cites this paper
• Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study.

  2022cites this paper
• Interobserver Variability in CT-based Morphologic Tumor Response Assessment of Colorectal Liver Metastases.

  2022cites this paper
• Chemotherapy-induced Reversion of Mutant RAS to Wild-type RAS in Metastatic Colorectal Cancer

  2022cites this paper
• Performance of Idylla™ RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer

  2022cites this paper
• Comparison of Next-Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment-Related Genomic Status in Patients with Metastatic Colorectal Cancer

  2022cites this paper
• Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis

  2022cites this paper
• Clinical Oncogenomics and Personalized Medicine in Colorectal Cancer for the Surgeon: What We Need to Know and What the Future Holds

  2022cites this paper
• Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer

  2022cites this paper
• Middle East and North Africa Registry to Characterize Rate of RAS Testing Status in Newly Diagnosed Patients with Metastatic Colorectal Cancer

  2022cites this paper
• Liver Endothelium Microenvironment Promotes HER3-mediated Cell Survival in KRAS Wild-type and Mutant Colorectal Cancer

  2021cites this paper
• Radiomics-Derived Data by Contrast Enhanced Magnetic Resonance in RAS Mutations Detection in Colorectal Liver Metastases

  2021cites this paper
• Bilateral adrenal haematoma complicated by adrenal insufficiency in a patient treated with bevacizumab

  2021cites this paper
• Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database.

  2021cites this paper
• KRAS A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases

  2021cites this paper
• Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment

  2021cites this paper
• Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer

  2021cites this paper
• KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine

  2021cites this paper
• Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931)

  2021cites this paper
• Discovery of a novel and a rare Kristen rat sarcoma viral oncogene homolog (KRAS) gene mutation in colorectal cancer patients

  2021cites this paper
• Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases

  2021cites this paper
• Liver Endothelium Promotes HER3-mediated Cell Survival in KRAS Wild-type and Mutant Colorectal Cancer Cells

  2021cites this paper
• The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil

  2021cites this paper
• Advances in Treatment Selection for Patients with Metastatic Colorectal Cancer

  2021cites this paper
• Research progress on KRAS mutations in colorectal cancer

  2021cites this paper
• The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program–Results of a Survey on Daily Practice Patterns for Patients with mCRC

  2021cites this paper
• Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer

  2021cites this paper
• Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer

  2020cites this paper
• Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost.

  2020cites this paper
• Decoding the Genomic Report for Radiologists.

  2020cites this paper
• Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit

  2020cites this paper
• NADPH oxidase 1 is highly expressed in human large and small bowel cancers

  2020cites this paper
• Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis

  2020cites this paper
• KRAS: From undruggable to a druggable Cancer Target.

  2020cites this paper
• Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression.

  2020cites this paper
• Associations between nutritional factors and KRAS mutations in colorectal cancer: a systematic review

  2020cites this paper
• Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy.

  2020cites this paper
• Diagnostic strategies towards clinical implementation of liquid biopsy RAS/BRAF circulating tumor DNA analyses in patients with metastatic colorectal cancer.

  2020cites this paper
• Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer

  2020cites this paper
• Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer

  2020cites this paper
• The conversion of RAS status in metastatic colorectal cancer patients after first‐line biological agent treatment

  2020cites this paper
• Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial

  2020cites this paper
• Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer

  2020cites this paper
• High frequency of microsatellite instability and its substantial co-existence with KRAS and BRAF mutations in Vietnamese patients with colorectal cancer

  2020cites this paper
• KRAS and BRAF Mutations as survival prognostic factors for Metastatic Colorectal Cancer patients after Lung metastasectomy: A Systematic Review and Meta-Analysis

  2020cites this paper
• High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer

  2019cites this paper
• Biomarkers in the Management of Metastatic Colorectal Cancer- a Mini Review

  2019cites this paper
• Predictive Biomarkers in Metastatic Colorectal Cancer: A Systematic Review.

  2019cites this paper
• KRAS and NRAS pyrosequencing screening in Tunisian colorectal cancer patients in 2015

  2019cites this paper
• Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol

  2019cites this paper
• Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital

  2019cites this paper
• Chemotherapy and Biologic Therapy in Rectal Cancer: An Update

  2019cites this paper
• Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy

  2019cites this paper
• Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis

  2019cites this paper
• KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer

  2019cites this paper
• Systemic treatment for metastatic colorectal cancer in the era of precision medicine

  2019cites this paper
• Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update.

  2019cites this paper
• Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies.

  2019cites this paper
• Drugging K-RasG12C through covalent inhibitors: Mission possible?

  2019cites this paper
• CT texture analysis for the prediction of KRAS mutation status in colorectal cancer via a machine learning approach.

  2019cites this paper
• Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies

  2019cites this paper
• Liquid biopsy in colorectal carcinoma: the search for potential prognostic and predictive biomarkers

  2019cites this paper
• Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis

  2019cites this paper
• Evaluation of the Idylla KRAS and NRAS mutation test in colorectal cancer tissue.

  2019cites this paper